Literature DB >> 23361134

Enantioselective formal synthesis of ent-rhynchophylline and ent-isorhynchophylline.

Mercedes Amat1, Carlos Ramos, Maria Pérez, Elies Molins, Pedro Florindo, Maria M M Santos, Joan Bosch.   

Abstract

Starting from (S)-tryptophanol, a formal synthesis of ent-rhynchophylline and ent-isorhynchophylline, involving stereoselective cyclocondensation, spirocyclization, and alkylation reactions, and the final adjustment of the oxidation level at the oxindole and piperidine moieties, is reported.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23361134     DOI： 10.1039/c2cc38540f

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  4 in total

1.  Metal-free [3 + 2 + 1]/[2 + 2 + 1] biscyclization: stereospecific construction with concomitant functionalization of indolizin-5(1H)-one.

Authors:  Tuan-Jie Li; Zhong-Qiu Liu; Hong-Mei Yin; Chang-Sheng Yao; Bo Jiang; Xiang-Shan Wang; Shu-Jiang Tu; Xiu-Ling Li; Guigen Li
Journal:  J Org Chem       Date:  2013-11-07       Impact factor: 4.354

2.  Rhynchophylline Downregulates Phosphorylated cAMP Response Element Binding Protein, Nuclear Receptor-related-1, and Brain-derived Neurotrophic Factor Expression in the Hippocampus of Ketamine-induced Conditioned Place Preference Rats.

Authors:  Youli Guo; Chaohua Luo; Genghong Tu; Chan Li; Yi Liu; Wei Liu; Ken Kin Lam Yung; Zhixian Mo
Journal:  Pharmacogn Mag       Date:  2018-02-20       Impact factor: 1.085

3.  Studies on the Enantioselective Synthesis of E-Ethylidene-bearing Spiro[indolizidine-1,3'-oxindole] Alkaloids.

Authors:  Nihan Yayik; Maria Pérez; Elies Molins; Joan Bosch; Mercedes Amat
Journal:  Molecules       Date:  2021-01-15       Impact factor: 4.411

4.  Enantiopure Indolo[2,3-a]quinolizidines: Synthesis and Evaluation as NMDA Receptor Antagonists.

Authors:  Nuno A L Pereira; Francesc X Sureda; Maria Pérez; Mercedes Amat; Maria M M Santos
Journal:  Molecules       Date:  2016-08-06       Impact factor: 4.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.